Breakdown | ||||
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
-36.00K | -382.00K | -256.00K | -303.00K | -18.00K | EBIT |
-70.42M | -55.99M | -41.84M | -22.89M | -20.52M | EBITDA |
-68.42M | -51.41M | -41.83M | -22.88M | -20.32M | Net Income Common Stockholders |
-68.46M | -51.79M | -38.78M | -21.28M | -20.33M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
126.87M | 101.90M | 150.41M | 41.05M | 9.96M | Total Assets |
132.74M | 123.72M | 152.42M | 42.61M | 10.96M | Total Debt |
2.23M | 2.48M | 188.00K | 14.42M | 410.00K | Net Debt |
-68.17M | -13.56M | -150.22M | -26.63M | -9.54M | Total Liabilities |
11.73M | 7.55M | 2.95M | 16.51M | 3.60M | Stockholders Equity |
121.00M | 116.17M | 149.47M | 26.10M | 7.37M |
Cash Flow | Free Cash Flow | |||
-57.37M | -44.63M | -39.62M | -20.44M | -24.17M | Operating Cash Flow |
-57.37M | -44.48M | -39.62M | -20.44M | -24.17M | Investing Cash Flow |
48.70M | -101.46M | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
63.03M | 11.57M | 148.98M | 51.53M | 22.55M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | $303.36M | ― | -0.23% | ― | 3087.25% | 97.11% | |
53 Neutral | $325.29M | ― | -74.36% | ― | ― | -10.43% | |
52 Neutral | $5.35B | 3.83 | -41.61% | 2.85% | 17.10% | 1.22% | |
46 Neutral | $167.27M | ― | -52.00% | ― | -100.00% | 38.72% | |
45 Neutral | $170.18M | ― | -43.31% | ― | 95.23% | 15.55% | |
42 Neutral | $181.28M | ― | -53.27% | ― | ― | 2.53% | |
38 Underperform | $163.24M | ― | -57.58% | ― | 15.18% | -9.47% |
On April 25, 2025, Rezolute, Inc. announced the closing of its underwritten offering, raising approximately $96.9 million through the sale of 24,940,769 shares of common stock and pre-funded warrants. The funds will be used for research and development, corporate expenses, and working capital. The offering saw participation from new and existing investors and was managed by Guggenheim Securities, with additional support from other financial institutions. Furthermore, a separate private placement is expected to close by May 7, 2025, potentially raising an additional $4.2 million.
Spark’s Take on RZLT Stock
According to Spark, TipRanks’ AI Analyst, RZLT is a Neutral.
Rezolute’s overall stock score is primarily influenced by its challenging financial performance and weak valuation metrics. The company’s strong equity position and recent positive corporate developments provide some optimism, but the overall outlook remains cautious due to persistent losses and operational inefficiencies.
To see Spark’s full report on RZLT stock, click here.
On April 23, 2025, Rezolute, Inc. announced the pricing of a registered direct offering involving the issuance of 20,786,923 shares of common stock and pre-funded warrants to purchase up to 6,905,385 shares, expected to close on April 24, 2025. The offering, managed by Guggenheim Securities, aims to raise approximately $84.2 million, potentially increasing to $96.9 million if additional options are exercised, with proceeds intended for research, development, and general corporate purposes.
Spark’s Take on RZLT Stock
According to Spark, TipRanks’ AI Analyst, RZLT is a Neutral.
Rezolute’s overall stock score reflects significant financial challenges and operational inefficiencies, partially offset by positive corporate developments and strategic improvements. While the stock has potential upside due to recent progress in clinical studies and strategic appointments, its financial health and technical indicators suggest cautious optimism.
To see Spark’s full report on RZLT stock, click here.
On April 23, 2025, Rezolute, Inc. announced a positive recommendation from an independent Data Monitoring Committee (DMC) to continue its Phase 3 sunRIZE study without increasing the sample size. This decision supports the company’s initial assumptions about the study’s design and efficacy, with enrollment expected to complete in May 2025 and topline results anticipated by December 2025. The study is evaluating the efficacy and safety of ersodetug in patients with congenital hyperinsulinism, a condition leading to recurrent hypoglycemia. The continuation of the study as planned suggests confidence in ersodetug’s potential as a best-in-class treatment for hyperinsulinism.
Spark’s Take on RZLT Stock
According to Spark, TipRanks’ AI Analyst, RZLT is a Neutral.
Rezolute’s overall stock score reflects significant financial challenges and operational inefficiencies, partially offset by positive corporate developments and strategic improvements. While the stock has potential upside due to recent progress in clinical studies and strategic appointments, its financial health and technical indicators suggest cautious optimism.
To see Spark’s full report on RZLT stock, click here.
Rezolute, Inc. announced the election of Erik Harris to its Board of Directors, effective March 25, 2025. Mr. Harris, deemed independent by Nasdaq standards, brings extensive experience from his roles at Ultragenyx Pharmaceutical Inc. and other life science companies. His appointment is expected to enhance Rezolute’s strategic direction, leveraging his commercial and management expertise. Mr. Harris will receive standard board compensation, including stock options, and his role is anticipated to strengthen the company’s industry positioning.